- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05395143
Study to Assess the Effect of Zinc in Atorvastatin Treated Hyperlipidemic Patients
May 24, 2022 updated by: Rumana Sharmin, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Study to Assess the Effect of Zinc in Atorvastatin Treated Hyperlipidemic Patients: a Randomized, Double-blind, Placebo-controlled Trial
This study was 8 weeks randomized, double-blind, placebo-controlled trial to assess the effect of zinc in Atorvastatin treated hyperlipidemic 92 patients.
Participants were assessed at baseline, and 8 weeks.
Subjects were randomized to receive either atorvastatin+placebo in one arm or atorvastatin +zinc 30mg tablet in another arm daily for 8 weeks.
The outcome was the measure of fasting lipid profile, sgpt, serum creatinine at baseline and after 8 weeks following the intervention.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Hyperlipidemia is a pathological disorder that includes raised concentration of serum cholesterol, LDL and triglycerides (TGs).
It is one of the most important triggering factors for the development of cardiovascular disease.
As a consequence, this disorder ultimately increases the mortality rate since cardiovascular disease (CVD) is globally the most common cause of death.
Various studies have demonstrated that the prevalence rate of CVD in Bangladesh is 0.33% to 19.6% (Malik, A., 1976 and Zaman, M.M. et al, 2007) and hyperlipidaemia is 46%.
Triglycerides, cholesterol, and lipoproteins are associated with the pathogenesis of coronary artery disease, especially atherosclerosis.
Atherosclerotic lesions may be the consequence of reduced serum high-density lipoprotein (HDL) and increased triglycerides level.
Triglyceride concentrations of about 1.7 mmol/L would be considered by many to be the point beyond which risk for coronary artery disease begins.
Triglyceride concentrations are commonly increased in diabetes mellitus, particularly the insulin-resistant type, noninsulin-dependent diabetes mellitus (NIDDM), and indicate an enhanced risk of coronary artery disease.
Hypercholesterolemia also enhances microvascular dysfunction by stimulating nitro-oxidative stress and induction of inflammation.
This mechanism leads to the development of myocardial infarction.
Normalization of serum lipid profile is the logical step to prevent atherosclerotic events such as myocardial infarction, ischaemic stroke, peripheral vascular disease and this will reduce the mortality rate.
As hyperlipidemia is a flexible condition, it can be modified by alteration of dietary habit, lifestyle change, and applications of various medications which interfere with lipid metabolism with the body.
In that case, statin medication is the most suitable therapy for hyperlipidemia.
The 2014 ACC (American College of Cardiology) / AHA (American Heart Association) guidelines have highlighted the benefits of statin therapy.
But despite the statins being very effective drug recommended target lipid lowering levels are not always achieved.
Moreover, long-term high-dose statin therapy may give rise to some adverse effects.
On the other hand, many other lipid lowering agents are available in the market but they are not able to achieve the target lipid lowering effect always and long term use of these drugs may promote some adverse effects.
They are also costly.
Therefore, exploration of alternative, affordable, efficacious with less adverse effects drugs should be the next point of interest for further study.
Besides, the repeated incidence of cardiovascular disease brings lingering hazards for the health.
This situation develops the requirement for an add-on lipid-lowering agent along with conventional statin therapy.
In that case, Zinc could be an agent added along with conventional statin therapy to normalize the lipid profile.
Zinc is an important micronutrient of the human body which is implicated as a component in various systemic wellbeing.
Several studies found that zinc might have protective effect in the prevention of atherosclerosis.
Effect of Zinc on lipid profile by some studies revealed that it can lower serum total cholesterol, LDL cholesterol, triglycerides and increase the HDL levels.
Therefore, the current study will explore the combination of lipid-lowering activity of atorvastatin and zinc.
This study will be a randomized, double blind, placebo controlled trial.
It will be conducted in the department of pharmacology, BSMMU in collaboration with the department of cardiology, BSMMU.A total of 92 patients suffering from hyperlipidemia will be selected according to inclusion and exclusion criteria.
The diagnosis of patients and the selection of drug and dosage would be performed by a senior professor of the cardiology department.
After completing the necessary formalities including informed consent of the patients, they will be enrolled and randomly allocated into two arms: control arm and intervention arm.
Patient in intervention arm would consist of 46 patients who will receive Atorvastatin plus Zinc (30 mg) tablet once daily orally for 8 weeks.
On the other hand, control arm would consist of 46 patients who will receive Atorvastatin plus placebo for 8 weeks.
The lipid profile will be measured at baseline and 8 weeks follow up
Study Type
Interventional
Enrollment (Anticipated)
92
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rumana Sharmin, MD
- Phone Number: 01956834094
- Email: fairysharmin03@gmail.com
Study Contact Backup
- Name: Prof.Md. Sayedur Rahman, FCPS.M Phil
- Phone Number: +8801971840757
- Email: srkhasru@bsmmu.edu.bd
Study Locations
-
-
-
Dhaka, Bangladesh, 1000
- Recruiting
- Bangabandhu Sheikh Mujib Medical University
-
Contact:
- Registrar
- Phone Number: +889661064
- Email: registrar@bsmmu.edu.bd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: 18 to 75 years
- Sex: both male and female
- Hyperlipidemic patients suffering from ischemic heart disease, diabetes mellitus, hypertension.
- A person can develop hyperlipidemia if they have one or a combination of the following: Diagnostic criteria for dyslipidemic patients (NCEP ATP III guideline) Total Cholesterol > 240 mg/dl LDL-C > 100 mg/dl Triglyceride > 150 mg/dl HDL-C < 40 mg/dl
Exclusion Criteria:
- Patients with renal impairment.
- Patient with history of active liver disease (e.g. jaundice, hepatitis, cirrhosis)
- Patients having hypersensitivity to drugs.
- Patients with any systemic diseases or having serious infections or terminal illness (e.g.-tuberculosis, HIV, malignant tumor)
- Pregnant woman
- lactating mother
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Atorvastatin and zinc
46 Hyperlipidemic patients are included in this arm who will receive Atorvastatin and Zinc.
Zinc tablets of 30mg will be used once daily according to randomization along with Atorvastatin.
|
Zinc sulfate tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
|
Placebo Comparator: Atorvastatin and placebo
46 Hyperlipidemic patients are included in this arm who will receive Atorvastatin and placebo.
Placebo tablets of 30mg will be used once daily according to randomization along with Atorvastatin.
|
Placebo tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change of TC
Time Frame: from the baseline after 8-week treatment;
|
from the baseline after 8-week treatment;
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change of LDL-C
Time Frame: from the baseline after 8-week treatment
|
from the baseline after 8-week treatment
|
Change of HDL-C
Time Frame: from the baseline after 8-week treatment
|
from the baseline after 8-week treatment
|
Change of TG
Time Frame: from the baseline after 8-week treatment
|
from the baseline after 8-week treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2021
Primary Completion (Anticipated)
July 10, 2022
Study Completion (Anticipated)
July 10, 2022
Study Registration Dates
First Submitted
May 24, 2022
First Submitted That Met QC Criteria
May 24, 2022
First Posted (Actual)
May 27, 2022
Study Record Updates
Last Update Posted (Actual)
May 27, 2022
Last Update Submitted That Met QC Criteria
May 24, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BSMMU/2021/4030
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperlipidemias
-
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....Not yet recruiting
-
Meir Medical CenterNot yet recruitingHypertriglyceridemiaIsrael
-
Esperion Therapeutics, Inc.RecruitingHypercholesterolemiaUnited States, Spain, Denmark, Canada, Netherlands, Germany
-
Jena University HospitalCharite University, Berlin, Germany; Ruhr University of Bochum; Technische Universität... and other collaboratorsRecruiting
-
Kowa Company, Ltd.Recruiting
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
University Health Network, TorontoRecruitingHyperlipidemiasCanada
-
Shahid Beheshti UniversityNational Nutrition and Food Technology InstituteCompleted
-
Novartis PharmaceuticalsActive, not recruitingHypercholesterolemiaUnited States, Germany, Hungary, Colombia, Mexico
-
University of BolognaSCHARPER SpaCompleted
Clinical Trials on Zinc sulfate
-
International Centre for Diarrhoeal Disease Research...Completed
-
Instituto Nacional de Salud Publica, MexicoUNICEFCompletedDiarrhea, Infantile | Diarrhoea;AcuteMexico
-
Hormozgan University of Medical SciencesCompleted
-
University of VermontNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting
-
Babylon UniversityMinistry of Health, IraqCompletedAsthenozoospermiaIraq
-
mahmoud hussein hadwanMinistry of Health, IraqCompleted
-
Mansoura UniversityCompleted
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedGastric Carcinoma | Unresectable Pancreatic Carcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Unresectable Esophageal CarcinomaUnited States
-
Universidad Nacional Autonoma de MexicoHospital General de Mexico; Hospital Pediatrico de CoyoacanCompletedPneumonia | Children, OnlyMexico
-
UCSF Benioff Children's Hospital OaklandChildren's Hospital Medical Center, CincinnatiCompletedCritical IllnessUnited States